There is increasing evidence for the beneficial effects of inhibiting the inflammasome or its products on various diseases, including neurodegenerative and autoimmune diseases and metabolic disorders. However, assessment of inflammasome inhibition in healthy volunteers is not straightforward. Therefore, we have developed and validated a whole blood-based assay to study the inflammasome in vitro and to use as an assay in clinical studies. Read more about the study in our new publication 'Whole blood assay as a model for in vitro evaluation of inflammasome activation and subsequent caspase-mediated interleukin-1 beta release'.
